脓毒症是外科病人常见的并发症，其实质是失控的炎性反应和凝血紊乱，二者相互影响可导致弥漫性血管内凝血（DIC），进一步发展可出现多器官功能衰竭甚至死亡。尽管祛除病因是治疗脓毒症DIC的根本策略，但在原发病未控制时，药物治疗仍发挥了重要作用。近年来，针对脓毒症DIC的药物治疗研究，尤其是抗凝和抗炎药物的基础及临床试验不断进行，凝血监测手段的进步亦推动了药物治疗的研发及应用。

Medication of sepsis with DIC        SU Lei, PENG Na. Department of Critical Care Medicine, Guangzhou General Hospital of Guangzhou Command, Guangzhou 510010, China
Corresponding author ：SU  Lei,  E-mail：slei_icu@163.com
Abstract    Sepsis is a common complication of surgical patients, with the nature of inter-related and inter-stimulative inflammation and coagulation dysfunction to induce the occurrence of DIC, even MODS and death. Although etiological elimination is the essential strategy in the treatment of sepsis with DIC, medication has certain important role when the primary disease is not under control. Recently, the experimental and clinical medication researches on the anticoagulation and antiinflammation are processing, and the advances of coagulation monitoring facilitate the development and application of the above medication.